TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Daily Photo Galleries

By The Associated Press
Thursday, March 28, 2013, 12:01 a.m.
 

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. Michigan man takes Heinz to court over Dip & Squeeze ketchup packet
  2. Stocks fall for 4th straight day; oil surges on Yemen strikes
  3. Toyota to carry new attitude into production
  4. Federal government eyes regulation of payday lending
  5. Federal Trade Commission cracks down on crooked vehicle sales
  6. Energy Department OKs loan of $259M to Alcoa to promote clean energy
  7. Court approves LightSquared’s bankruptcy exit plan
  8. One secret Facebook doesn’t want you to know
  9. Stop foreign dumping, U.S. Steel CEO Longhi tells Congress
  10. Heinz merging with Kraft in mega-deal; headquarters to stay in Pittsburgh
  11. Pittsburgh angles to keep Heinz headquarters in merger